S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

DexCom (DXCM) Stock Forecast & Price Target

$133.86
-2.66 (-1.95%)
(As of 04/17/2024 ET)

DexCom Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 15 Analyst Ratings

Analysts' Consensus Price Target

$141.40
5.63% Upside
High Forecast$165.00
Average Forecast$141.40
Low Forecast$100.00
TypeCurrent Forecast
4/18/23 to 4/17/24
1 Month Ago
3/19/23 to 3/18/24
3 Months Ago
1/18/23 to 1/18/24
1 Year Ago
4/18/22 to 4/18/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$141.40$136.67$132.94$125.11
Predicted Upside5.63% Upside20.81% Upside20.68% Upside16.86% Upside
Get DexCom Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

DXCM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DexCom Stock vs. The Competition

TypeDexComMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside5.65% Upside930.61% Upside11.83% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$153.00 ➝ $163.00+16.74%
4/3/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$148.00 ➝ $161.00+15.86%
3/12/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$165.00+24.02%
1/23/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$147.00 ➝ $151.00+16.79%
12/19/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$135.00 ➝ $150.00+21.61%
12/13/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$110.00 ➝ $136.00+13.55%
12/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$101.00 ➝ $122.00+4.54%
10/17/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$160.00 ➝ $100.00+21.42%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
10/16/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$110.00+37.81%
10/10/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$155.00 ➝ $145.00+74.36%
8/21/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$153.00 ➝ $130.00+22.58%
7/31/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$115.00 ➝ $138.00+4.25%
7/28/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$135.00 ➝ $150.00+8.19%
7/28/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$135.00 ➝ $150.00+7.87%
6/26/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$134.00 ➝ $150.00+19.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:42 PM ET.

DXCM Price Target - Frequently Asked Questions

What is DexCom's consensus rating and price target?

According to the issued ratings of 15 analysts in the last year, the consensus rating for DexCom stock is Moderate Buy based on the current 2 hold ratings, 12 buy ratings and 1 strong buy rating for DXCM. The average twelve-month price prediction for DexCom is $141.40 with a high price target of $165.00 and a low price target of $100.00. Learn more on DXCM's analyst rating history.

Do Wall Street analysts like DexCom more than its competitors?

Analysts like DexCom more than other Medical companies. The consensus rating score for DexCom is 2.93 while the average consensus rating score for medical companies is 2.68. Learn more on how DXCM compares to other companies.

Does DexCom's stock price have much upside?

According to analysts, DexCom's stock has a predicted upside of 19.56% based on their 12-month stock forecasts.

What analysts cover DexCom?

DexCom has been rated by Citigroup, Raymond James, Royal Bank of Canada, and UBS Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:DXCM) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners